HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Fineline Cube
3 Min Read
Summarize with AI

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TAGRISSO monotherapy in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations and MET overexpression. The combination also showed very encouraging clinical benefit in overall survival (OS).

- Advertisement -

Trial Snapshot – SANOVO Phase III

ItemDetail
SponsorHutchMed (NASDAQ: HCM; HKG: 0013)
TrialSANOVO, Phase III (China)
RegimenORPATHYS (savolitinib) + TAGRISSO (osimertinib) vs. TAGRISSO monotherapy
PopulationTreatment-naïve locally advanced/metastatic NSCLC with EGFR mutations and MET overexpression
Primary EndpointPFS — met with statistical significance
Secondary EndpointOS — clinically meaningful improvement in ITT population
Populations AnalyzedHigh-level MET (IHC 3+) and ITT (IHC 2+/3+)

Clinical Evidence – Progression-Free Survival

PopulationMedian PFS (Combination)Median PFS (TAGRISSO Monotherapy)Risk ReductionStatistical Significance
ITT (IHC 2+/3+)24.9 months (>2 years)13.8 months (~1 year)44% (HR 0.56; 95% CI: 0.43–0.74)p < 0.0001
High-level MET (IHC 3+)24.8 months11.1 months55% (+13.7 months median PFS extension)Not disclosed

Clinical Evidence – Overall Survival (ITT Population)

EndpointCombination ArmControl Arm (TAGRISSO)Benefit
Median OS44.5 months34.9 months+9.6 months
Estimated 3-Year Survival Rate67.4%47.4%+20.0 percentage points
OS Curve DynamicsCurves continued to separate with longer follow-up–Magnitude of benefit expanded over time
  • Subgroup Consistency: Consistent PFS and OS benefits were observed across all pre-specified ITT subgroups, reinforcing the robustness of the combination effect.

Market Impact & Outlook

  • First-Line Paradigm Shift: Targeting MET overexpression — a known resistance and poor-prognosis factor in EGFR-mutant NSCLC — with upfront savolitinib plus osimertinib challenges the current third-generation EGFR TKI monotherapy standard in biomarker-selected patients.
  • Biomarker-Defined Opportunity: The dual-population benefit (both IHC 3+ and IHC 2+/3+) supports routine MET IHC testing alongside EGFR mutation screening at diagnosis, potentially reshaping Chinese NSCLC diagnostic pathways.
  • Franchise Synergy: SANOVO strengthens the commercial pairing of ORPATHYS (HutchMed/AstraZeneca) and TAGRISSO (AstraZeneca), deepening the MET-directed oncology franchise in one of the world’s largest lung cancer markets.
  • Durable Survival Signal: The widening OS separation and 67.4% three-year survival suggest a long-tail benefit characteristic of effective targeted combinations — a compelling value proposition for payers and guidelines.
  • Next Steps: Regulatory submission plans were not disclosed in the announcement.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the SANOVO study, the ORPATHYS plus TAGRISSO combination, and potential regulatory submissions or commercialization. Actual results may differ due to risks including final data maturation, regulatory review decisions, reimbursement outcomes, and competitive dynamics in EGFR-mutant NSCLC treatment.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *